Patients will be randomised evenly to receive either 50mg or 100mg of LB-102, or a placebo, for a duration of six weeks.
Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophreniaAdvanced LB-102 into late-stage development in ...
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE)-- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results